Home | Contact Us | Brochure  | User Guide
0
Username
Password
Forgot Password
Capitaline Newswire App Google Play Capitaline Newswire App Store
02 Apr 2026 00:04 Sensex 73,319.55 185.23 (0.25%) || Nifty 22,713.10 33.70 (0.15%) 00
  AMC
  Single Scheme
  Multi Schemes
  Comparison
  NFO
  Charts
  MF Updates
  Miscellaneous
  Defined Sets
News
Top Equity Holdings by AMC
Interview with Fund Managers Back
01 Apr 2026 13:15
Marksans Pharma gains on securing USFDA approval for Benzonatate Capsules
Marksans Pharma soared 7.92% to Rs 169.60 after the company has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Benzonatate Capsules USP, 100 mg and 200 mg.

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, marketed by Pfizer Inc.

Benzonatate is a non-narcotic antitussive that works by numbing stretch receptors in the respiratory tract, thereby suppressing the cough reflex. It is commonly used for the symptomatic relief of persistent cough associated with conditions such as bronchitis, pneumonia, and other respiratory infections.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company’s consolidated net profit increased 8.26% year-on-year to Rs 113.20 crore, despite a 10.64% jump in revenue from operations to Rs 754.42 crore in Q3 FY26 compared with Q3 FY25.

Powered by Capital Market - Live News
Other Stories
Vikran Engineering bags L...
 (4-Apr  16:12)
Bajaj Housing Finance clo...
 (4-Apr  15:37)
Dabur India expects domes...
 (4-Apr  14:27)
Kernex Microsystems bags ...
 (4-Apr  13:17)
J&K Bank’s gross advances...
 (4-Apr  12:00)
Bajaj Finance Q4 deposits...
 (4-Apr  11:02)
HDFC Bank’s average depos...
 (4-Apr  10:16)
L&T Finance Q4 retail dis...
 (4-Apr  10:01)
Avenue Supermarts Q4 reve...
 (4-Apr  09:00)
RBL Bank's total business...
 (3-Apr  17:34)
  FAQs  |  SEBI  |  AMFI  |  BSE  |  NSE
Glossary  |  Disclaimer   |  Privacy Policy   © Copyright 2022 All rights Reserved. Capital Market Publishers India Pvt. Ltd.